In vitro inhibition of human acetyl- and butyrylcholinesterase by Narcissus poeticus L. (Amaryllidaceae) flower absolute

International Journal of Essential Oil Therapeutics

Volumn 2, Issue 3, 2008, Pages 105-110

  Okello, E J ^a   Dimaki, C ^a   Howes, M J R ^b   Houghton, P J ^c   Perry, E K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b JODRELL LABORATORY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Absolute; Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Dementia; Inhibition; Kinetics; Narcissus

Indexed keywords

ACETYLCHOLINESTERASE; BENZENE DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; GALANTAMINE; HERBACEOUS AGENT; TERPENOID;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME INHIBITION; FLOWER; IN VITRO STUDY; MASS FRAGMENTOGRAPHY; NARCISSUS; NARCISSUS POETICUS; NONHUMAN;

EID: 77954200927     PISSN: 19614209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lawrence, AD, Sahakian, BJ. Alzheimer's disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord. 1995;9(Suppl 2):43-49.
2. Benzi, G, Moretti, A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Euro J Pharmacol. 1998;346:1-13.
3. Geula C, Darvesh S. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. Drugs Today (Barc). 2004 Aug; 40(8):711-21.
4. Annicchiarico R, Federici A, Pettenati C, Caltagirone C. Rivastigmine in Alzheimer's disease: Cognitive function and quality of life. Ther Clin Risk Manag. 2007;3(6):1113-23.
5. Heinrich M, Teoh HL. Galanthamine from snowdrop - the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol. 2004; 92:147-162.
6. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's Disease. Drugs. 2000;60(5):1095-122.
7. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci. 1990;46(21):1553-8.
8. Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A. Modulation of nicotinic receptor activity in the central nervous system: A novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15(Suppl 1):S19-25.
9. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer's type. Neuropathol Appl Neurobiol. 1978;4:273-77.
10. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, Taylor P, Hinrichs SH, Lockridge O. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther. 2000;293:896-902.
11. Mesulam MM, Guillozet A, Shaw P, Levery A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central pathways and can use butyrylcholinesterase to hydrolyse acetylcholine. Neurosci. 2002;110:627-39.
12. Mesulam MM, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyse acetylcholine in the normal and Alzheimer's brain. Neurobiol Dis. 2002;9:88-93.
13. Costa J, Anand R, Cutler N, et al.. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial with rivastigmine in Alzheimer's patients. Proc Am Psych Assoc. 1999; Poster NR 561.
14. Nordberg A, Darreh-Shori T, Svenson A, Guan Z.. AChE and BuChE activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J Neurol Sci. 2001;187 (Suppl.):P0144.
15. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine:correlation with cognitive benefits. J Neural Transm. 2002;109:1053-65.
16. Smallwood J, Brown R, Coulter F, Irvine E, Copland C. Aromatherapy and behaviour disturbances in dementia: a randomised controlled trial. Int J Geriatr Psychiat. 2001;16(10):1010-3.
17. Holmes C, Hopkins V, Hensford C, MacLaughlin V, Wilkinson D, Rosenvinge H. Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. Int J Geriat Psychiat. 2000:17(4):305-8.
18. Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a doubleblind, placebo controlled trial with Melissa. J Clin Psychiat. 2002;63(7):553-58.
19. Lee SY. The effect of lavender aromatherapy on cognitive function, emotion, and aggressive behaviour of elderly with dementia. Taehan Kanho Hakhoe Chi. 2005;35(2):303-12.
20. Lin PW, Chan WC, Ng BF, Lam LC. Efficacy of aromatherapy (Lavandula angustifolia) as an intervention for agitated behaviours in Chinese older persons with dementia: a crossover randomised trial. Int J Geriatr Psychiat. 2007;22(5):405-10.
21. Nguyen Q, Oatan C. The use of aromatherapy to treat behavioural problems in dementia. Int J Geriatr Psychiat. 2008;23:337-46.
22. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961; 7: 88-95.
23. Palmer T. Understanding Enzymes, 4th Edition. New York: Prentice Hall; 1995.
24. Dixon M. The determination of enzyme inhibitor constants. Biochem J. 1953;55(1):170-71.
25. Adams RP. Identification of Essential Oil Components by Gas Chromatography / Quadrupole Mass Spectroscopy. Illinois, USA: Allured Publishing Corporation; 2001.
26. Ausloos P, Clifton C, Lias SG, Shamin A, Stein S. NIST/EPA/ NIH Mass Spectral Database (v. 4). Gaitherburg, USA: US Department of Commerce; 1992.
27. Davies NW. Gas-chromatographic retention indexes of monoterpenes and sesquiterpenes on methyl silicone and carbowax 20M phases. J Chromatogr. 1990;503:1-24.
28. Dobson HEM, Arroyo J, Bergström G, Groth I. Interspecific variation in floral fragrances within the genus Narcissus. Biochem Syst Ecol. 1997;25:685-706.
29. van Dort HM, Jägers PP, ter Heide R, van der Weerdt AJA. Narcissus trevithian and Narcissus geranium: analysis and synthesis of compounds. J Agric Food Chem. 1993;41;2063-75.
30. Houghton PJ, Howes M-JR. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals. 2005;14:6-22.
31. Houghton PJ, Ren Y, Howes M-JR. Acetylcholinesterase inhibitors from plants and fungi. Nat Prod Rep. 2006;23:181-199.
32. Ryan MF, Byrne O. Plant-insect coevolution and inhibition of acetylcholinesterase. J Chem Ecol. 1988;14:1965-1975.
33. Picollo MI, Toloza AC, Mougabure Cueto G, Zygadlo J, Zerba E. Anticholinesterase and pediculicidal activities of monoterpenoids. Fitoterapia. 2008; Article in press.
34. Perry NSL, Houghton PJ, Theobald A, Jenner P, Perry EK. In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol. 2000;52:895-902.
35. Savelev S, Okello E, Perry NSL, Wilkins RM, Perry EK. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav. 2003;75:661-68.
36. Miyazawa M, Yamafuji C. Inhibition of acetylcholinesterase activity by tea tree oil and constituent terpenoids. Flav Fragr J. 2006;21:198-201
37. Tanaka R. Effects of benzyl alcohol on adenosine triphosphate, p-nitrophenylphosphatase and acetylcholinesterase in rat erythrocyte membrane. J Toxicol Sci. 1984;9(2):109-16.
38. Marco L, do Carmo Carreiras M. Galanthamine, a natural product for the treatment of Alzheimer's disease. Recent Patents CNS Drug Discov. 2006;1(1):105-11.
39. Rahman A, Khalid A, Sultana, N. Ghayur MN, Mesaik MA, Khan MR, Gilani AH, Choudhary MI. New natural cholinesterase inhibiting and calcium channel blocking quinoline alkaloids. J Enz Inhib & Med Chem. 2006;21:703-10.
40. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C. et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer ß-amyloid peptide in rodent. PNAS. 2005;102:17213-18.
41. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002;14(Suppl 1):77-91.